What's in a name? Bence Jones protein

Rathore, Roshni; Coward, R. A.; Woywodt, Alexander

doi:10.1093/ckj/sfs127

Cited by 11 publications

(7 citation statements)

References 38 publications

(50 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The first documentation of the existence of FLCs dates from 1845 [ 5 ], when a 38-year-old greengrocer from London developed bone pains and generalized swelling. His physician noticed a unique protein in his urine and sent a sample to Henry Bence Jones, the chemical pathologist from whom these proteins would take their name.…”

Section: Pathogenesis: the Role Of Flcsmentioning

confidence: 99%

Treatment of multiple myeloma with renal involvement: the nephrologist’s view

Favà

Fulladosa

Montero

et al. 2018

Clinical Kidney Journal

View full text Add to dashboard Cite

Renal injury is a common complication in multiple myeloma (MM). In fact, as many as 10% of patients with MM develop dialysis-dependent acute kidney injury related to increased free light chain (FLC) production by a plasma cell clone. Myeloma cast nephropathy (MCN) is the most prevalent pathologic diagnosis associated with renal injury, followed by light chain deposition disease and light chain amyloidosis. Several FLC removal techniques have been explored to improve kidney disease in MM but their impact on renal clinical outcomes remains unclear. According to the evidence, high cut-off haemodialysis should be restricted to MM patients on chemotherapy with histological diagnosis of MCN and haemodialysis requirements. From our perspective, more efforts are needed to improve kidney outcomes in patients with MM and renal failure.

show abstract

Section: Pathogenesis: the Role Of Flcsmentioning

confidence: 99%

Treatment of multiple myeloma with renal involvement: the nephrologist’s view

Favà

Fulladosa

Montero

et al. 2018

Clinical Kidney Journal

View full text Add to dashboard Cite

show abstract

“…Bence Jones Proteins (BJP) are monoclonal immunoglobulin light chains, found in the urine of patients with plasma cell dyscrasias that were initially described by Henry Bence Jones in 1845 [ 21 ]. They are the first cancer biomarker to have been discovered.…”

Section: Laboratory Assays For the Detection And Measurement Of Monoc...mentioning

confidence: 99%

Performance Characteristics and Limitations of the Available Assays for the Detection and Quantitation of Monoclonal Free Light Chains and New Emerging Methodologies

Giles,

Karunanithi

2024

Antibodies

View full text Add to dashboard Cite

Light chain measurements form an essential component of the testing strategy for the detection and monitoring of patients with suspected and/or proven plasma cell disorders. Urine-based electrophoretic assays remain at the centre of the international guidelines for response assessment but the supplementary role of serum-free light chain (FLC) assays in response assessment and the detection of disease progression due to their increased sensitivity has been increasingly recognised since their introduction in 2001. Serum FLC assays have also been shown to be prognostic across the spectrum of plasma cell disorders and are now incorporated into risk stratification scores for patients with monoclonal gammopathy of undetermined significance (MGUS), smouldering multiple myeloma, and light chain amyloidosis (AL amyloidosis), as well as being incorporated into the criteria for defining symptomatic multiple myeloma. There are now multiple different commercially available serum FLC assays available with differing performance characteristics, which are discussed in this review, along with the implications of these for patient monitoring. Finally, newer methodologies for the identification and characterisation of monoclonal FLC, including modifications to electrophoretic techniques, mass spectrometry-based assays and Amylite, are also described along with the relevant published data available regarding the performance of each assay.

show abstract

“…Tokom 1843. godine, Aleksander Tomas Mek Bin, ugledni četrdesetčetvorogodišnji trgovac iz Londona, počeo je da se pojačano zamara što ga je pri-moravalo da zastaje pri dužem hodu. Primetio je da ima i češći nagon za mokrenjem, kao i da mu je "veš stalno natopljen mokraćom iako nije mokrio" (1).…”

Section: Tajanstvena Bolest Gospodina Mek Binaunclassified

“…Interesantno je da je Mek Intajer podjednako bio posvećen humanitarnom radu, budući da je kao lekar radio u dvema ustanovama za "nemoćne i bolesne" (Metropolitan Convalescent Institution i Western General Dispensary). Uslovi rada u ovakvim bolnicama podrobno su opisani u delu "Oliver Tvist" Čarlsa Dikensa, objavljenog 1838. godine (1).…”

Section: Kratke Crtice Iz Biografijeunclassified

See 1 more Smart Citation

Bence Jones Protein –The First Tumour Marker in History of Medicine

Govedarović¹

2019

AMM

View full text Add to dashboard Cite

Bence Jones protein is generally accepted term for protein described in urine of myeloma patients. Today, qualitative, as well as quantitative determination of Bence Jones protein serve as routine analyses for diagnosis and screening of myeloma and skeletal affections. Although Bence Jones is not the first to recognize the characteristics of the urine of the diseased, his merit is that he recognized the importance of this protein in patients with myeloma. He is considered as the pioneer in medical chemistry and is one of the first doctors who emphasized the importance of chemical analysis for the diagnosis of the disease. His discovery of proteinuria in multiple myeloma has long been the only biochemical test for cancer until the seventies of the twentieth century, with the discovery of carcinoembrion antigen (CEA) and alpha-fetoprotein (alpha-FP) It can rightly be said that a protein named after him is the first tumor marker in the history of medicine.

show abstract

What's in a name? Bence Jones protein

Cited by 11 publications

References 38 publications

Treatment of multiple myeloma with renal involvement: the nephrologist’s view

Treatment of multiple myeloma with renal involvement: the nephrologist’s view

Performance Characteristics and Limitations of the Available Assays for the Detection and Quantitation of Monoclonal Free Light Chains and New Emerging Methodologies

Bence Jones Protein –The First Tumour Marker in History of Medicine

Contact Info

Product

Resources

About